Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOPG liposome
- Development stage
- Preclinical
- Lead developer
- Brigham and Women's Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DOPG liposomes are anionic lipid-based nanoparticles primarily composed of the phospholipid 1,2-dioleoyl-sn-glycero-3-phospho-(1-rac-glycerol) (DOPG). These liposomes are frequently utilized as research tools and model systems to investigate the influence of negative surface charge on the pharmacokinetic properties, biodistribution, and cellular uptake of nanomedicines. In preclinical studies, such as those involving B16 melanoma models, DOPG liposomes have been used to evaluate preferential internalization by various immune cell populations, including dendritic cells and macrophages, within the tumor microenvironment and lymphoid organs like the spleen. They serve as a comparative model alongside cationic (e.g., DOTAP) and neutral (e.g., DOPC) liposomes to optimize drug delivery systems for cancer immunotherapy and other therapeutic applications.
- Other names
- anionic DOPG NPDOPG nano-liposome1,2-dioleoyl-sn-glycero-3-phospho-(1-rac-glycerol) liposome
Beyond the preview
Go deeper on DOPG liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOPG liposome.